| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HC8; Proteasome component C8; PSC8; psmA3;;PSMA3 |
| WB Predicted band size | 28 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PSMA3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于PSMA3抗体的3篇参考文献及其概括内容：
1. **文献名称**：*"Proteasome subunit α3 interacts with influenza A virus NS1 protein to inhibit antiviral response"*
**作者**：Li C, et al.
**摘要**：该研究利用PSMA3特异性抗体进行免疫共沉淀实验，发现流感病毒NS1蛋白通过结合蛋白酶体α3亚基抑制宿主抗病毒反应，揭示了PSMA3在病毒感染中的调控作用。
2. **文献名称**：*"Development of a monoclonal antibody specific for PSMA3 and its application in proteasome activity assays"*
**作者**：Yamamoto S, et al.
**摘要**：作者开发了一种高特异性抗PSMA3单克隆抗体，验证了其在Western blot和免疫组化中的有效性，并证明其可用于检测蛋白酶体复合体组装异常相关疾病中的PSMA3表达水平。
3. **文献名称**：*"Proteasome dysfunction in Parkinson's disease: Role of α-subunit antibodies in biomarker discovery"*
**作者**：Wang H, et al.
**摘要**：研究通过PSMA3抗体检测帕金森患者脑组织样本，发现蛋白酶体α亚基(包括PSMA3)的异常聚集与蛋白酶体功能损伤相关，提示其作为神经退行性疾病生物标志物的潜力。
注：以上为示例性内容，实际文献需通过PubMed或Web of Science检索确认。建议使用关键词"PSMA3 antibody"或"Proteasome alpha 3 antibody"筛选近年研究。
PSMA3 (Proteasome 20S Subunit Alpha 3) is a core component of the 20S proteasome, a multicatalytic proteinase complex responsible for degrading ubiquitinated proteins in the ubiquitin-proteasome pathway. As part of the proteasome's regulatory machinery, PSMA3 plays a critical role in maintaining cellular protein homeostasis, regulating processes such as cell cycle progression, apoptosis, and stress response. Antibodies targeting PSMA3 are widely used in research to study proteasome structure, function, and dysregulation in diseases like cancer, neurodegenerative disorders, and autoimmune conditions.
These antibodies are typically developed using recombinant PSMA3 protein or synthetic peptides corresponding to specific epitopes. They enable the detection and quantification of PSMA3 expression in various experimental applications, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Validation often involves knockout cell lines or tissue samples to confirm specificity. In cancer research, PSMA3 antibodies help investigate proteasome activity alterations linked to tumor progression and drug resistance, particularly in the context of proteasome inhibitor therapies (e.g., bortezomib). In neurological studies, they aid in exploring connections between proteasome dysfunction and protein aggregation pathologies like Alzheimer's and Parkinson's diseases. Additionally, PSMA3 serves as a biomarker for assessing proteasome composition changes under physiological or pathological stress conditions.
×
